Cystoid macular edema

Tryfon G Rotsos, Marilita M Moschos, Tryfon G Rotsos, Marilita M Moschos

Abstract

We review the epidemiology, pathophysiology, and etiology of cystoid macular edema (CME). Inflammatory, diabetic, post-cataract, and macular edema due to age-related macular degeneration is described. The role of chronic inflammation and hypoxia and direct macular traction is evaluated in each case according to different views from the literature. The different diagnostic methods for evaluating the edema are described. Special attention is given to fluoroangiography and the most modern methods of macula examination, such as ocular coherence tomography and multifocal electroretinography. Finally, we discuss the treatment of cystoid macular edema in relation to its etiology. In this chapter we briefly refer to the therapeutic value of laser treatment especially in diabetic maculopathy or vitrectomy in some selected cases. Our paper is focused mainly on recent therapeutic treatment with intravitreal injection of triamcinolone acetonide and anti-VEGF factors like bevacizumab (Avastin), ranibizumab (Lucentis), pegaptamid (Macugen), and others. The goal of this paper is to review the current status of this treatment for macular edema due to diabetic maculopathy, central retinal vein occlusion and post-cataract surgery. For this reason the results of recent multicenter clinical trials are quoted, as also our experience on the use of intravitreal injections of anti-VEGF factors and we discuss its value in clinical practice.

Keywords: OCT; anti-VEGF; cystoid macular edema; fluoroangiography; multifocal electroretinography.

Figures

Figure 1
Figure 1
A 58-year-old man with pseudophakic CME. The pretreatment OCT shows an increase of the central retinal thickness (A), and the mf-ERG reveals a craterlike depression of the foveal and perifoveal area (B). Twelve months after treatment the OCT depicts the improvement of the central retinal thickness (C) and the mf-ERG shows a real recovery of the electrical activity of the foveal (area 1) and parafoveal (area 2) area (D). Abbreviations: CME, cystoid macular edema; mf-ERG, multifocal electroretinogram; OCT, optical coherence tomography.
Figure 2
Figure 2
OCT recordings of the right eye of a 60-year-old male patient at presentation (A), 1 month after treatment (B) and 3 months after treatment (C). The pretreatment OCT showed an increase of central retinal thickness. Three months after treatment the OCT depicted the decrease of the retinal thickness of the fovea. Abbreviation: OCT, optical coherence tomography.
Figure 3
Figure 3
3D topographic plot and mf-ERG traces of the same eye at presentation (A), 1 month after treatment (B) and 3 months after treatment (C). Before treatment the mf-ERG revealed a craterlike depression of the foveal and perifoveal area. Three months after treatment the mf-ERG showed an improvement of the electrical activity of the fovea (area 1) and perifovea (area 2). Abbreviations: 3D, three dimensional; mf-ERG, multifocal electroretinogram.

References

    1. Abe T, Hayasaka S, Nagaki Y, et al. Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. J Cataract Refract Surg. 1999;25:1286–8.
    1. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457–61.
    1. Aiello LP, Bursell SE, Devris T, et al. Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes. 1999;48:A19.
    1. Androudi S, Letko E, Meniconi M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005;13:205–12.
    1. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98:271–82.
    1. Avitabile T, Longo A, Reibaldi A, et al. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695–702.
    1. Bergman M, Laatikainen L. Cystoid macular oedema after complicated cataract surgery and implantation of an anterior chamber lens. Acta Ophthalmol (Copenh) 1994;72:178–80.
    1. Binz N, Graham CE, Simpson K, et al. Long-term effect of therapeutic laser photocoagulation on gene expression in the eye. FASEB J. 2006;20:383–5.
    1. Bonnet S. [Repercussions of cataract surgery on the development of cystoid macular edema in the diabetic patient] Bull Soc Belge Ophtalmol. 1995;256:127–9.
    1. Bradford JD, Wilkinson CP, Bradford RH, et al. Cystoid macular edema following extracapsular cataract extraction and posterior chamber intraocular lens implantation. Retina. 1988;8:161–4.
    1. Browning DJ, Glassman AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008;115:1366–71.
    1. Burnett J, Tessler H, Isenberg S, et al. Double-masked trial of fenoprofen sodium: treatment of chronic aphakic cystoid macular edema. Ophthalmic Surg. 1983;14:150–2.
    1. Camras CB, Fardeau C, Cassoux N, et al. [Ocular manifestations of Behçet’s disease] Ann Med Interne (Paris) 1999;150:529–34.
    1. Cassoux N, Lumbroso L, Bodaghi B, et al. Cystoid macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy. Br J Ophthalmol. 1999;83:47–9.
    1. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Central Vein Occlusion Study Group. report. Ophthalmology. 1995;102:1425–33.
    1. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706–12.
    1. Coscas G, Gaudric A. Natural course of nonaphakic cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):471–84.
    1. Cox SN, Hay E, Bird AC, et al. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190–5.
    1. Cunningham ET, Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747–57.
    1. Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology. 1996;103:1846–53.
    1. Dodds EM, Lowder CY, Meisler DM, et al. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm. 1999;7:85–92.
    1. Dowler JG, Hykin PG, Hamilton AM, et al. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. Ophthalmology. 2000;107:457–62.
    1. Dowler JG, Sehmi KS, Hykin PG, et al. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology. 1999;106:663–8.
    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report no 1. Arch Ophthalmol. 1985;103:1796–806.
    1. Early Treatment Diabetic Retinopathy Study Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:254–64.
    1. Early Treament Diabetic Retinopathy Study. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study. Research Group. Ophthalmology. 1991;98(Suppl 5):766–85.
    1. Federman JL, Annesley WH, Jr, Sarin LK, et al. Vitrectomy and cystoid macular edema. Ophthalmology. 1980;87:622–8.
    1. Finkelstein D. Ischemic macular edema. Recognition and favourable natural history in branch vein occlusion. Arch Ophthalmol. 1992;110:1427–34.
    1. Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107:1445–52.
    1. Flach AJ. Topical nonsteroidal antinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1–11.
    1. Flanagan DW. Current management of established diabetic eye disease. Eye. 1993;7(Pt 2):302–8.
    1. Foster RE, Lowder CY, Meisler DM, et al. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients. Ophthalmology. 1992;99:1234–41.
    1. Fung WE. Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized investigation. Ophthalmology. 1985;92:1102–11.
    1. Gardner TW, Antonetti DA, Barber AJ, et al. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(Suppl 2):S253–62.
    1. Gass JD, Anderson DR, Davis EB, et al. A clinical, fluorescein angiographic, and electron microscopic correlation of cystoid macular edema. Am J Ophthalmol. 1985;100:82–6.
    1. Gass JDM, Norton EWD. Cystoid macular edema and papilledema following cataract extraction: A fluorescein fundoscopic and angiographic study. Arch Ophthalmol. 1966;76:646–61.
    1. Ghafour IM, Foulds WS, Allan D, et al. Contrast sensitivity in diabetic subjects with and without retinopathy. Br J Ophthalmol. 1982;66:492–5.
    1. Glacet-Bernard A, Coscas G, Chabanel A, et al. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology. 1996;103:551–60.
    1. Grant MB, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;13:1275–93.
    1. Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97:297–309.
    1. Hainsworth DP, Pearson PA, Conklin JD, et al. Sustained release intravitreal dexamethasone. J Ocul Pharmacol Ther. 1996;12:57–63.
    1. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105:360–70.
    1. Helm CJ, Holland GN, Webster RG, et al. Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis. Ophthalmology. 1997;104:838–43.
    1. Henderly DE, Genstler AJ, Rao NA, et al. Pars planitis. Trans Ophthalmol Soc UK. 1986;105(Pt 2):227–32.
    1. Henderly DE, Haymond RS, Rao NA, et al. The significance of the pars plana exudates in pars planitis. Am J Ophthalmol. 1987;103:669–71.
    1. Hikichi T, Trempe CL. Role of thevitreous in the prognosis of peripheral uveitis. Am J Ophthalmol. 1993;116:401–5.
    1. Hikichi T, Konno S, Trempe CL, et al. Role of the vitreous in central retinal vein occlusion. Retina. 1995;15:29–33.
    1. Hirokawa H, Takahashi M, Trempe CL, et al. Vitreous changes in peripheral uveitis. Arch Ophthalmol. 1985;103:1704–7.
    1. Hitchings RA. Aphakic macular oedema: A two year follow-up study. Br J Ophthalmol. 1977;61:628–30.
    1. Holland GN. Immune recovery uveitis. Ocul Immunol Inflamm. 1999;7:231–5.
    1. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254:1178–81.
    1. Ibanez HE, Lesher MP, Singerman LJ, et al. Prospective evaluation of the effect of pseudophakic cystoid macula edema on contrast sensitivity. Arch Ophthalmol. 1993;111:1635–9.
    1. Irvine AR, Bresky R, Crowder BM, et al. Macular edema after cataract extraction. Ann Ophthalmol. 1971;3:1234–40.
    1. Irvine AR. A newly defined vitreous syndrome following cataract surgery: interpreted according to recent concepts of the structure of the vitreous. Am J Ophthalmol. 1953;36:599–619.
    1. Irvine SR. A newly defined vitreous syndrome following cataract surgery, interpreted according to recent concepts of the structure of the vitreous. Am J Ophthalmol. 1953;36:599–619.
    1. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279–84.
    1. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–33.
    1. Jaffe NS, Luscombe SM, Clayman HM, et al. A fluorescein angiographic study of cystoid macular edema. Am J Ophthalmol. 1981;92:775–7.
    1. Jampol LM, Sanders DR, Kraff MC, et al. Prophylaxis and therapy of aphakic cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):535–9.
    1. Jampol LM, Sanders DR, Kraff MC, et al. Prophylaxis and therapy of aphakic cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):535–9.
    1. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57–61.
    1. Jones WL. Fluid blood level in cystoid space resulting from central retinal vein occlusion. J Am Optom Assoc. 1998;69:129–32.
    1. Katzen LE, Fleischman JA, Trokel S, et al. YAG laser treatment of cystoid macular edema. Am J Ophthalmol. 1983;95:589–92.
    1. Kersten AJ, Althaus C, Best J, et al. Cystoid macular edema following immune recovery and treatment with cidofovir for cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:893–6.
    1. Kita M, Marmor MF. Effects on retinal adhesive force in vivo of metabolically active agents in the subretinal space. Invest Ophthalmol Vis Sci. 1992;33:1883–7.
    1. Koutsandrea C, Moschos MM, Brouzas D, et al. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: An OCT and mf-ERG study. Retina. 2007;27:159–64.
    1. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859–66.
    1. Kylstra JA, Brown JC, Jaffe GJ, et al. The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology. 1999;106:2068–73.
    1. Lightman S, Chan CC. Immune mechanisms in choroido-retinal inflammation in man. Eye. 1990;4:345–53.
    1. Lightman S, Greenwood J. Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Clin Exp Immunol. 1992;88:473–7.
    1. Lightman SL, Caspers-Velu LE, Hirose S, et al. Angiography with fluorescein-labeled dextrans in a primate model of uveitis. Arch Ophthalmol. 1987;105:844–8.
    1. Loewenstein A, Goldstein M. Intravitreal triamcinolone acetonide for diabetic macula edema. Isr Med Assoc J. 2006;8:426–7.
    1. Mainster MA, Timberlake GT, Webb RH, et al. Scanning laser ophthalmoscopy. Clinical applications. Ophthalmology. 1982;89:852–7.
    1. Mason JO, III, Colagross CT, Vail R, et al. Diabetic vitrectomy: risks, prognosis, future trends. Curr Opin Ophthalmol. 2006;17:281–5.
    1. Miyake Y, Miyake K, Shiroyama N, et al. Classification of aphakic cystoid macular edema with focal macular electroretinograms. Am J Ophthalmol. 1993;116:576–83.
    1. Molnar I, Poitry S, Tsacopoulos M, et al. Effect of laser photocoagulation on oxygenation of the retina in miniature pigs. Invest Ophthalmol Vis Sci. 1985;26:1410–4.
    1. Moschos MM, Moschos MN. Intraocular bevacizumab for macular edema due to CRVO. A multlifocal-ERG and OCT study. Doc Ophthalmol. 2008;116:147–52.
    1. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmol. 1988;95:1335–9.
    1. Okhravi N, Lightman SL, Towler HM, et al. Assessment of visual outcome after cataract surgery in patients with uveitis. Ophthalmology. 1999;106:710–22.
    1. Oshima Y, Emi K, Yamanishi S, et al. Quantitative assessment of macular thickness in normal subjects and patients with diabetic retinopathy by scanning retinal thickness analyzer. Br J Ophthalmol. 1999;83:54–61.
    1. Peterson M, Yoshizumi MO, Hepler R, et al. Topical indomethacin in the treatment of chronic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 1992;230:401–5.
    1. Recchia FM, Ruby AJ, Carvalho-Recchia CA, et al. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol. 2005;139:447–54.
    1. Reese AB, Jones IS, Cooper WC, et al. Macular changes secondary to vitreous traction. Am J Opthtalmol. 1967;64:544–9.
    1. Ripandelli G, Coppé AM, Capaldo A, et al. Optical coherence tomography. Semin Ophthalmol. 1998;13:199–202.
    1. Salzman J, Seiple W, Carr R, et al. Electrophysiological assessment of aphakic cystoid macular oedema. Br J Ophthalmol. 1986;70:819–24.
    1. Schlaegel TF, Weber JC. The macula in ocular toxoplasmosis. Arch Ophthalmol. 1984;102:697–8.
    1. Sutter EG, Tran D. The field topography of ERG component in man. The photopic luminance response. Vision Res. 1992;32:433–66.
    1. Tolentino FI, Schepens CL. ; Edema of posterior pole after cataract extraction: A biomicroscopic study. Arch Ophthalmol. 1965;74:781–6.
    1. Wakefield D, McCluskey P, Penny R, et al. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104:847–51.
    1. Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992;4:1–5.
    1. Weiner A, Christopoulos VA, Gussler CH, et al. Foveal cone function in nonproliferative diabetic retinopathy and macular edema. Invest Ophthalmol Vis Sci. 1997;38:1443–9.
    1. Wolter JR. Cystoid Macular edema in vitreo-retinal traction. Ophthalmic Surg. 1981;12:900–4.
    1. Yanoff M, Fine BS, Brucker AJ, et al. Pathology of humancystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):505–11.
    1. Zeimer RC, Shahidi M, Mori MT, et al. In vivo evaluation of a non-invasive method to measure the retinal thickness in primates. Arch Ophthalmol. 1989;107:1006–9.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir